Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
5
×
fda
5
×
life sciences
national blog main
boston top stories
clinical trials
national top stories
san francisco blog main
deals
new york blog main
new york top stories
novartis
san francisco top stories
amgen
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
investing
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accent therapeutics
aducanumab
akouos
alder biopharmaceuticals
alirocumab
What
fda
5
×
medicines
5
×
drug
new
approval
developing
ipo
acquire
activity
affects
agreed
americans
amgen
approvals
approved
billion
bio
biogen
blueprint
brings
cancer
candidate
candidates
cash
cholesterol
clamped
class
company
compound
covid
currently
date
deal
delays
developed
economic
fast
frequency
gets
head
Language
unset
Current search:
fda
×
biotech
×
medicines
×
fda
×
" boston blog main "
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines